Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -1.55 is 46% above its 5-year average of -2.90, near the high end of its 5-year range (-5.39–-1.24).
24.50% below its 12-month average of -1.25.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.80.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
EARNINGS PER SHARE (EPS)
-1.55
EARNINGS PER SHARE (EPS) AVG TTM
-1.25
EARNINGS PER SHARE (EPS) AVG 3Y
-1.99
EARNINGS PER SHARE (EPS) AVG 5Y
-2.90
EARNINGS PER SHARE (EPS) AVG 10Y
-314.78
EARNINGS PER SHARE (EPS) AVG 15Y
-1382.14
EARNINGS PER SHARE (EPS) AVG 20Y
-1215.91
CURRENT VS TTM AVG
-24.50%
CURRENT VS 3Y AVG
+21.91%
CURRENT VS 5Y AVG
+46.49%
CURRENT VS 10Y AVG
+99.51%
CURRENT VS 15Y AVG
+99.89%
CURRENT VS 20Y AVG
+99.87%
Achieve Life Sciences, Inc.
Market Cap
$738.63M
Earnings Per Share (EPS)
-1.55
TTM Avg
-1.25
3Y Avg
-1.99
5Y Avg
-2.90
Market Cap
$746.26M
Earnings Per Share (EPS)
-1.41
TTM Avg
-1.23
3Y Avg
-0.97
5Y Avg
-1.16
Market Cap
$724.49M
Earnings Per Share (EPS)
-0.62
TTM Avg
-0.28
3Y Avg
-0.16
5Y Avg
-0.10
Market Cap
$745.29M
Earnings Per Share (EPS)
-141.65
TTM Avg
-20.37
3Y Avg
-24.20
5Y Avg
-22.76
Market Cap
$722.04M
Earnings Per Share (EPS)
-4.74
TTM Avg
-5.08
3Y Avg
-296.60
5Y Avg
-1006.80
Market Cap
$718.69M
Earnings Per Share (EPS)
1.24
TTM Avg
2.06
3Y Avg
1.25
5Y Avg
1.30
Market Cap
$712.76M
Earnings Per Share (EPS)
-2.13
TTM Avg
-2.04
3Y Avg
-2.21
5Y Avg
-1.87
Market Cap
$765.17M
Earnings Per Share (EPS)
-1.18
TTM Avg
-1.05
3Y Avg
-1.11
5Y Avg
-0.92
Market Cap
$778.67M
Earnings Per Share (EPS)
0.84
TTM Avg
0.43
3Y Avg
-11.54
5Y Avg
-7.53
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Achieve Life Sciences, Inc. (ACHV) | $738.63M | -1.55 | -1.25 | -1.99 | -2.90 |
| Candel Therapeutics, Inc. (CADL)vs › | $746.26M | -1.41 | -1.23 | -0.97 | -1.16 |
| Cytek Biosciences, Inc. (CTKB)vs › | $724.49M | -0.62 | -0.28 | -0.16 | -0.10 |
| Faeth Therapeutics, Inc. (FTH)vs › | $745.29M | -141.65 | -20.37 | -24.20 | -22.76 |
| Avalo Therapeutics, Inc. (AVTX)vs › | $722.04M | -4.74 | -5.08 | -296.60 | -1006.80 |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $718.69M | 1.24 | 2.06 | 1.25 | 1.30 |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $712.76M | -2.13 | -2.04 | -2.21 | -1.87 |
| Design Therapeutics, Inc. (DSGN)vs › | $765.17M | -1.18 | -1.05 | -1.11 | -0.92 |
| Mesa Laboratories, Inc. (MLAB)vs › | $778.67M | 0.84 | 0.43 | -11.54 | -7.53 |
| Attovia Therapeutics, Inc. (ATTO)vs › | $778.41M | N/A | -1.23 | -1.23 | -1.23 |
Trailing EPS (TTM)
$-1.55
Forward EPS (Est.)
$-1.46
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -1.25 |
| 2024-12-31 | -1.24 |
| 2023-12-31 | -1.50 |
| 2022-12-31 | -3.95 |
| 2021-12-31 | -4.05 |
| 2020-12-31 | -5.39 |
| 2019-12-31 | -39.15 |
| 2018-12-31 | -72.29 |
| 2017-12-31 | -441.47 |
| 2016-12-31 | -1478.66 |
| 2015-12-31 | -1413.63 |
| 2014-12-31 | -3189.89 |
| 2013-12-31 | -4772.10 |
| 2012-12-31 | -3432.80 |
| 2011-12-31 | -3318.18 |
| 2010-12-31 | -3938.65 |
| 2009-12-31 | 1905.36 |
| 2008-12-31 | -1677.57 |
| 2007-12-31 | -13971.30 |
| 2006-12-31 | -25323.97 |
| 2005-12-31 | -27363.19 |
| 2004-12-31 | -30260.84 |
| 2003-12-31 | -23106.18 |
| 2002-12-31 | -33726.96 |
| 2001-12-31 | 1844.14 |
| 2000-12-31 | -8873.71 |
| 1999-12-31 | 1914.85 |
| 1998-12-31 | -51612.90 |
| 1997-12-31 | 4608.29 |
| 1996-12-31 | 7906.98 |
